<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1339250</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jog</surname>
<given-names>Neelakshi R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/610707"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wagner</surname>
<given-names>Catriona A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1481456"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aberle</surname>
<given-names>Teresa</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2161425"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chakravarty</surname>
<given-names>Eliza F.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arriens</surname>
<given-names>Cristina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2663149"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guthridge</surname>
<given-names>Joel M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1330288"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>James</surname>
<given-names>Judith A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/585232"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation</institution>, <addr-line>Oklahoma City, OK</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Departments of Medicine and Pathology, University of Oklahoma Health Science Center</institution>, <addr-line>Oklahoma City, OK</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Xia Li, Dalian Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Natalia V. Giltiay, University of Washington, United States</p>
<p>Caroline Jefferies, Cedars Sinai Medical Center, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Judith A. James, <email xlink:href="mailto:jamesj@omrf.org">jamesj@omrf.org</email>
</p>
</fn>
<fn fn-type="present-address" id="fn003">
<p>&#x2020;Present address: Neelakshi R. Jog, Translational Early Development- Immunology, Bristol Myers Squibb, Princeton, NJ, United States</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1339250</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>11</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>02</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Jog, Wagner, Aberle, Chakravarty, Arriens, Guthridge and James</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Jog, Wagner, Aberle, Chakravarty, Arriens, Guthridge and James</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Neutrophil dysregulation, particularly of a low-density subset, is associated with systemic lupus erythematosus (SLE); however, the exact role of normal-density neutrophils in SLE remains unknown. This study compares activation and functional phenotypes of neutrophils from SLE patients and healthy controls to determine potential contributions to SLE pathogenesis. Surface activation markers and release of neutrophil extracellular traps (NETs), granule proteins, and cytokines/chemokines were measured in resting and stimulated neutrophils from SLE patients (n=19) and healthy controls (n=10). Select miRNA and mRNA involved in neutrophil development and function were also measured. Resting SLE neutrophils exhibited fewer activation markers compared to control neutrophils, and activation markers were associated with different plasma cytokines/chemokines in SLE patients compared to healthy controls. However, activation markers increased similarly in SLE and control neutrophils following stimulation with a TLR7/8 agonist, neutrophil growth factors, and bacterial mimic. At the resting state, SLE neutrophils produced significantly more CXCL10 (IP-10), with trends toward other increased cytokines/chemokines. Following stimulation, SLE neutrophils produced fewer NETs and proinflammatory cytokines compared to control neutrophils but more MMP-8. In addition, SLE neutrophils expressed less miR130a, miR132, miR27a, and miR223. In conclusion, SLE neutrophils exhibit distinct functional responses compared to control neutrophils. These functional differences may result from differential gene expression via miRNAs. Furthermore, the differences in functional phenotype of SLE neutrophils suggest that they may contribute to SLE differently dependent on the inflammatory milieu.</p>
</abstract>
<kwd-group>
<kwd>neutrophils</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>autoimmunity</kwd>
<kwd>cytokines</kwd>
<kwd>neutrophil extracellular traps</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="22"/>
<page-count count="8"/>
<word-count count="3065"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Neutrophils are rapid-acting, short-lived cells, forming the first line of defense against invading microbes through various processes, including producing cytokines, releasing granules containing antimicrobial proteins (i.e., lactoferrin) and proteases (i.e., matrix metalloproteinases [MMPs]), and generating neutrophil extracellular traps (NETs). Neutrophil dysregulation, particularly increased NETosis, is linked to autoimmune diseases like systemic lupus erythematosus (SLE). In particular, a proinflammatory neutrophil subset termed low-density granulocytes (LDGs) is elevated in SLE patients (<xref ref-type="bibr" rid="B1">1</xref>). LDGs are transcriptionally distinct, producing more IFN&#x3b3;, TNF&#x3b1;, type I IFNs, and NETs compared to autologous and healthy control normal-density neutrophils (referred to here as traditional neutrophils [TNs]) (<xref ref-type="bibr" rid="B2">2</xref>&#x2013;<xref ref-type="bibr" rid="B4">4</xref>), suggesting possible mechanisms by which LDGs influence SLE pathogenesis.</p>
<p>In contrast to LDGs, NET formation is similar between SLE and healthy TNs (<xref ref-type="bibr" rid="B4">4</xref>), suggesting that TNs might exert different functional responses or not contribute to SLE pathogenesis. However, studies on the role of TNs in SLE pathogenesis are limited and somewhat conflicting. For example, one study suggested that TNs are pathogenic through the upregulation of IFN&#x3b1; mRNA (<xref ref-type="bibr" rid="B2">2</xref>), while another found that neutrophils may be regulatory by restricting CD4+ T cell proliferation (<xref ref-type="bibr" rid="B5">5</xref>). This study compares the activation and functional responses of SLE and healthy TNs to understand their contributions to SLE pathogenesis.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Patients</title>
<p>SLE patients and healthy controls were recruited at the Oklahoma Medical Research Foundation (OMRF) through the Oklahoma Rheumatic Disease Research Cores Center. All patients met the American College of Rheumatology (ACR) and ACR/EULAR criteria for SLE classification (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>), and all participants provided written informed consent before inclusion in the study. All studies were performed in accordance with the Helsinki Declaration and approved by the OMRF Institutional Review Board.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Neutrophil isolation</title>
<p>Neutrophils were isolated from whole blood using dextran sedimentation as previously described (<xref ref-type="bibr" rid="B8">8</xref>). Briefly, blood was collected in vacutainers with citrate anti-coagulant, and peripheral blood mononuclear cells were separated by density gradient centrifugation. Red blood cells were sedimented using dextran. Residual red blood cells in supernatants were lysed and enriched TNs were used for experiments. Neutrophil enrichment resulted in &gt;95% viability and &gt;97% purity.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Flow cytometry</title>
<p>Neutrophils were cultured with HBSS with calcium and magnesium + 1% BSA (HBSS++) alone (unstimulated control) or with 10&#xb5;M R848 (InvivoGen), 0.1&#xb5;g/ml G-CSF (Peprotech Inc), or 0.1&#xb5;g/ml G-CSF + GM-CSF for 30 minutes or 300nM of the bacterial mimic formyl methionine leucine phenyl-alanine (fMLF, Sigma) for 3 minutes. Cells were stained with CD66b-PerCP-Cy5.5, CD11b-FITC, CD62L-BV650, and CD35-PE antibodies (all from Biolegend) for 20 minutes on ice. After washing, cells were fixed in 1% paraformaldehyde. Data were acquired with LSRII or FACSCelesta (BD Biosciences) cytometers and analyzed using FlowJo Software (Tree Star).</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Neutrophil and plasma soluble mediators</title>
<p>Neutrophils were cultured for 3h in HBSS++ alone (unstimulated) or with R848 or a combination of G-CSF and GM-CSF (as above). Supernatants were collected by centrifugation, aliquoted, and stored at -20&#xb0;C. Neutrophil granule proteins and cytokines, as well as plasma cytokines, were measured using custom xMAP assays (R&amp;D systems) as previously described (<xref ref-type="bibr" rid="B9">9</xref>). Data were acquired on the BioPlex200 array system (Bio-Rad Technologies, Hercules, CA). Plates with &gt;60% of samples below the standard range were excluded from subsequent analyses. Plasma levels of BLyS and APRIL were measured by ELISA according to the manufacturer&#x2019;s instructions (R&amp;D Systems).</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>NETosis</title>
<p>Neutrophils were seeded on poly-L Lysine coated chambered cover glass (Nunc/Labtek, 50,000 cells/chamber) with or without 10&#xb5;M R848 or 0.1&#xb5;g/ml G-CSF+GM-CSF for 4h, followed by fixation with 4% paraformaldehyde for 30min. After permeabilization with 0.25% triton X-100, cells were blocked with blocking buffer (5% goat serum in 1x PBS), and incubated overnight with polyclonal anti-MPO (Dako) and monoclonal anti-histone (Millipore) in blocking buffer at 4&#xb0;C. Cells were stained with Rhodamine Red conjugated anti-rabbit and FITC conjugated anti-mouse antibodies. DNA was visualized by DAPI. NETs were visualized using a Zeiss LSM 710 confocal microscope, and data were analyzed with ImageJ.</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>miRNA and mRNA quantitation</title>
<p>Total RNA was extracted from neutrophils using a Quick RNA miniprep kit (Zymo Research). For miRNA quantitation, 10ng total RNA was reverse transcribed and pre-amplified using Qiagen miScript II RT and PreAmp kits. miRNA was quantitated using miScript SYBR Green PCR Kit and miScript Primer Assays on an ABI 7900HT thermal cycler. Total RNA was also used to quantify select mRNA expression using Fluidigm Biomark HD and delta gene assays per the manufacturer&#x2019;s instructions (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table 1</bold>
</xref>).</p>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>Statistical analyses</title>
<p>For all analyses with 2 groups, comparisons were made using a 2-tailed Mann-Whitney test. A 2-way ANOVA with Sidak&#x2019;s multiple comparisons test was used for analyses with 2 independent groups. Spearman&#x2019;s rank correlation was used for correlation analyses. Heatmaps were created using Complexheatmap v.4.2 in R. All other analyses were performed using GraphPad Prism 9, and p-values less than 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Traditional neutrophils from SLE patients exhibit a reduced basal activation phenotype</title>
<p>To determine whether TNs from SLE patients are more activated due to the existing inflammatory milieu, we determined the basal surface expression of neutrophil activation markers by flow cytometry. Surprisingly, compared to healthy controls (n=10), TNs from SLE patients (n=19) exhibited significantly lower expression of CD66b (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>), specifically in patients with low disease activity (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;1</bold>
</xref>). In addition, there was a trend towards reduced CD35, particularly in those with high disease activity, and increased CD62L expression compared to those from controls (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1A&#x2013;C</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;1</bold>
</xref>). CD11b expression was similar in TNs from SLE patients and healthy controls (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>). These data suggest that TN from controls and patients with high disease activity have similar baseline activation; however, TNs from low disease activity patients may have suppressed basal activation. The expression of activation markers did not differ based on corticosteroid usage (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;2</bold>
</xref>). Consistent with differing inflammatory environments, activation markers were associated with different plasma cytokines/chemokines in SLE patients compared to healthy controls (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>). In particular, neutrophil activation positively correlated with the expression of SCF in SLE patients but not controls.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>SLE traditional neutrophils are less activated at the resting state, but maintain their ability to respond to external stimuli. <bold>(A)</bold> CD66b, <bold>(B)</bold> CD35, <bold>(C)</bold> CD62L, and <bold>(D)</bold> CD11b expression was determined on traditional neutrophils isolated from controls or SLE patients using flow cytometry. Statistical significance was determined using a Mann-Whitney test. <bold>(E)</bold> Heatmap of Spearman&#x2019;s rank correlation coefficients for plasma soluble mediator concentrations (MFI fold-change over control) that were significantly associated with CD66b or CD62L expression on traditional neutrophils isolated from controls or SLE patients. <bold>(F)</bold> CD66b, <bold>(G)</bold> CD35, <bold>(H)</bold> CD11b, and <bold>(I)</bold> CD62L expression was determined on unstimulated or stimulated traditional neutrophils isolated from controls or SLE patients using flow cytometry. Statistical significance was determined using a 2-way ANOVA with Sidak&#x2019;s multiple comparisons test. Lines indicate mean+SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1339250-g001.tif"/>
</fig>
<p>Excessive stimulation, as expected in SLE, may result in neutrophil exhaustion, which could contribute to the reduced activation phenotype observed in TNs from SLE patients. To test this possibility, we stimulated TNs from SLE and healthy controls with the TLR7/8 ligand R848, G-CSF with or without GM-CSF, and the bacterial mimic fMLF. TNs from SLE patients upregulated activation markers similarly to those from controls (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1F&#x2013;I</bold>
</xref>), suggesting that TNs are not exhausted and can respond to external stimuli. Similar trends were observed in patients with low and high disease activity, although differences were less pronounced in those with high disease activity (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;3</bold>
</xref>).</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>SLE traditional neutrophils exhibit a distinct phenotype at rest and following stimulation</title>
<p>We next determined if TN functional phenotype, specifically NETosis, degranulation, and cytokine/chemokine production, differed from control TNs (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;2</bold>
</xref>). At resting conditions, the percent of NET-forming neutrophils and release of the granule proteins lactoferrin, MMP-2, MMP-8, and MMP-9 did not differ between SLE and control TNs (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;4</bold>
</xref>). However, resting SLE TNs produced significantly more IP-10, with trends toward other increased cytokines/chemokines, such as IL-21, TRAIL, APRIL, CCL3, and BLyS, compared to control TNs (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2A&#x2013;G</bold>
</xref>). In addition, TNs from patients with high disease activity released significantly less lactoferrin at rest compared to those with low disease activity and controls, while TNs from patients with low disease activity released significantly more lactoferrin compared to controls (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;3</bold>
</xref>). TN functional responses did not differ based on corticosteroid usage (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;4</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>The functional phenotype of SLE traditional neutrophils differs under basal conditions and following stimulation compared to control traditional neutrophils. <bold>(A)</bold> Volcano plot of the difference between unstimulated functions in traditional neutrophils isolated from SLE patients and controls. Red dots indicate those significantly higher in neutrophils from SLE patients compared to those from controls. Levels of secreted <bold>(B)</bold> IP-10, <bold>(C)</bold> IL-21, <bold>(D)</bold>&#xa0;TRAIL, <bold>(E)</bold> APRIL, <bold>(F)</bold> CCL3, and <bold>(G)</bold> BLyS from unstimulated control or SLE traditional neutrophils as measured by flow cytometry. <bold>(H)</bold> Volcano plot of the difference between G-CSF+GM-CSF-stimulated functions in traditional neutrophils isolated from SLE patients and controls. Red dots indicate those significantly higher and blue dots indicate those significant lower in neutrophils from SLE patients compared to those from controls. Levels of secreted <bold>(I)</bold> MMP-8, <bold>(J)</bold> IL-8, <bold>(K)</bold> IL-1&#x3b2;, <bold>(L)</bold> IL-23, and <bold>(M)</bold> IL-1Ra from unstimulated control or SLE traditional neutrophils as measured by flow cytometry. <bold>(N)</bold> Percent of neutrophils with NETs was determined by microscopy following DNA and myeloperoxidase staining in G-CSF+GM-CSF-stimulated traditional neutrophils isolated from controls or SLE patients. Statistical significance was determined using a Mann-Whitney test. Lines represent mean+SEM. *p&lt;0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1339250-g002.tif"/>
</fig>
<p>Despite higher soluble mediator production at rest, SLE TNs only released more MMP-8 following stimulation with R848 (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;5</bold>
</xref>) or G-CSF and GM-CSF (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2H, I</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;6</bold>
</xref>). Furthermore, TNs from patients with low or high disease activity released significantly more lactoferrin compared to those from controls following G-CSF and GM-CSF stimulation (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;3</bold>
</xref>). In contrast, following G-CSF and GM-CSF stimulation, control TNs produced significantly more NETs, IL-8, and IL-1&#x3b2;, with trends towards increased IL-1Ra and IL-23, compared to SLE TNs (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2J&#x2013;N</bold>
</xref>). TN functions were similar in SLE patients on or off corticosteroids (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;4</bold>
</xref>).</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>SLE traditional neutrophils show differences in the expression of select miRNA</title>
<p>As SLE and control TNs displayed different functional responses, we hypothesized that gene expression may also differ. Therefore, we performed a targeted gene expression analysis for genes that differ in TNs isolated from patients with other immune-mediated diseases and healthy controls (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). In a subset of patients and controls, <italic>CSFF3, ID2, KIT, NFKBIA, NFKBIE, PIM1, TNFAIP3, TNFSF8, TRAF3</italic>, <italic>miR9, miR138, miR143, miR146a</italic>, and <italic>miR155</italic> expression did not differ between control (n=4) and SLE (n=8) TNs (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;7</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>8</bold>
</xref>). However, the expression of <italic>miR130a, miR132, miR27a, and miR223</italic> was significantly higher in control TNs compared to SLE TNs (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>miRNA expression differs between control and SLE traditional neutrophils. Levels of <bold>(A)</bold> miR130a, <bold>(B)</bold> miR132, <bold>(C)</bold> miR27a, and <bold>(D)</bold> miR223 were measured by real-time PCR in traditional neutrophils isolated from controls or SLE patients. Statistical significance was determined using a Mann-Whitney test. Lines represent mean+SEM. *p&lt;0.05, **p&lt;0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1339250-g003.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>We found that despite reduced activation at resting, TNs from SLE patients can respond to external stimulation; however, SLE TNs exhibit different functional responses compared to control TNs. For example, resting SLE TNs produced more of the IFN-associated chemokine IP-10, which is increased right before SLE classification and flare (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B12">12</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>), and contributes to T cell chemoattraction and activation (<xref ref-type="bibr" rid="B15">15</xref>). In addition, resting SLE TNs may produce more APRIL and IL-21. Although the consequences of APRIL and IL-21 production by TNs remain unknown, previous studies have found that, in healthy individuals and during infection, neutrophils provide B cell help within the spleen through APRIL and IL-21, inducing immunoglobulin class switching, somatic hypermutation, and antibody production (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). Therefore, TNs may also contribute to autoantibody production in SLE.</p>
<p>Interestingly, following stimulation, SLE TNs secreted less proinflammatory cytokines and NETs but released more MMP-8, while TNs from SLE patients with low or high disease activity released more lactoferrin, compared to control TNs, suggestive of increased degranulation. However, levels of the degranulation marker MMP-9 did not significantly differ. Although the role of MMP-8 in SLE is unknown, other MMPs, such as MMP-9, may play a regulatory role in SLE, potentially by cleaving autoantigens, reducing their immunogenicity and promoting immune complex clearance (<xref ref-type="bibr" rid="B16">16</xref>). In addition, lactoferrin may inhibit NET formation (<xref ref-type="bibr" rid="B17">17</xref>), consistent with the reduced NETosis we observed in SLE TNs following stimulation. Thus, SLE TNs may play a more anti-inflammatory role in the presence of G-CSF and GM-CSF, suggesting that they contribute to SLE pathogenesis differently, dependent on the inflammatory environment.</p>
<p>A limited number of studies have investigated the functional phenotypes of SLE compared to healthy TNs, and results have been somewhat conflicting. These studies found that at rest and following stimulation with PMA, SLE and healthy TNs exhibit similar functional responses, including ROS production, NETosis, and cytokine expression (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Consistent with these studies, we found similar CD66b expression on SLE and healthy TNs, which is a marker for granules required for ROS generation. However, in contrast to other studies, following G-CSF/GM-CSF stimulation, our data suggest that SLE TNs produce less NETs and proinflammatory cytokines compared to healthy TNs. This may be a result of different external stimulations used in our and other studies, as we did not see these differences following R848 stimulation. Consistent with functional differences, SLE and healthy TNs differ in gene expression and DNA methylation, specifically of IFN-regulated genes (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Thus, our study and others demonstrate potential functional differences between SLE and healthy TNs; however, studies encompassing a more comprehensive analysis of neutrophil functional responses are needed. Although an evaluation of autologous LDGs was not included in this study, our data suggest that SLE TNs may have different functional responses compared to SLE LDGs, which are hyperresponsive and produce elevated proinflammatory cytokines and NETs compared to autologous TNs (<xref ref-type="bibr" rid="B2">2</xref>&#x2013;<xref ref-type="bibr" rid="B4">4</xref>). Based on the gene expression profiles and morphology of LDGs, some studies postulate that LDGs are immature cells that are prematurely released from the bone marrow due to increased recruitment during inflammation (<xref ref-type="bibr" rid="B19">19</xref>), which may explain these functional differences. In addition, the increase in LDGs and excessive inflammation observed in SLE may indicate an increase in immature or exhausted SLE TNs; however, our data show that TNs express markers of mature neutrophils and retain the ability to respond to external stimuli, suggesting that SLE TNs are not immature or exhausted. Instead, we found that following stimulation, SLE TNs may be anti-inflammatory as they produce less proinflammatory cytokines and NETs. Future studies will assess whether TN functions differ based on the frequency of LDGs, providing further insight into the relationship between LDGs and TNs in SLE patients.</p>
<p>Our results suggest that TN responses are regulated differently in SLE compared to healthy individuals. Although the exact nature of differential regulation is unclear, we found that miRNAs implicated in neutrophil development and function (<xref ref-type="bibr" rid="B20">20</xref>), miR130a, miR132, miR27a, and miR223, are significantly lower in SLE neutrophils. miR130a is highly expressed in early neutrophil precursors and reduced significantly upon maturation (<xref ref-type="bibr" rid="B21">21</xref>); therefore, a reduction of miR-130a in SLE TNs supports the notion that SLE TNs are not more immature compared to control TNs. In contrast, miR132, miR27a, and miR223 exhibit high expression in more mature neutrophils, with a further increase of miR132 in activated neutrophils (<xref ref-type="bibr" rid="B21">21</xref>), suggesting that these miRNAs may instead influence the observed functional differences. For example, although the role of miR223 in neutrophils in SLE is unknown, miR223 inhibits neutrophil activation and neutrophil-driven inflammation in tuberculosis and hepatic injury mouse models (<xref ref-type="bibr" rid="B22">22</xref>). Thus, the reduced levels of miR223 may contribute to the increased production of proinflammatory mediators in unstimulated SLE TNs. However, future studies are needed to determine how these miRNAs contribute to TN functions in SLE.</p>
<p>This study was limited by the small sample size, especially in the miRNA and mRNA analyses. Furthermore, gene expression analyses were determined using targeted qPCR and the use of bulk RNA-sequencing may reveal additional differences. Finally, the SLE patients included in this study were treated and had long-standing disease, and additional differences may be revealed in populations of treatment-na&#xef;ve patients.</p>
<p>Together, our data suggest that TNs may contribute to SLE pathogenesis; however, their contributions may differ compared to LDGs and depend on the inflammatory environment. The increased production of IP-10, APRIL, and IL-21 by SLE TNs suggest that resting SLE TNs may contribute to SLE pathogenesis through the modulation of T cell and humoral responses. In contrast, in the presence of G-CSF and GM-CSF, SLE TNs produce less inflammatory cytokines and more MMP-8 and lactoferrin, suggesting a potential regulatory role. However, future mechanistic studies are needed to determine how these functional differences impact SLE pathogenesis.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Oklahoma Medical Research Foundation Institutional Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>NJ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. CW: Formal analysis, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. TA: Data curation, Investigation, Methodology, Writing &#x2013; review &amp; editing. EC: Data curation, Investigation, Methodology, Writing &#x2013; review &amp; editing. CA: Data curation, Investigation, Methodology, Writing &#x2013; review &amp; editing. JG: Data curation, Investigation, Methodology, Writing &#x2013; review &amp; editing. JJ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported in part by the National Institute of Allergy, and Infectious Diseases [UM1AI144292, U01AI176244], the National Institute of Arthritis, Musculoskeletal and Skin Diseases [P30AR073750, R01AR072401], a pilot grant from the Oklahoma Shared Clinical and Translational Research Center Institutional Development Award from the National Institute of General Medical Sciences [U54GM104938], and the Lupus Research Alliance [NJ].</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We would like to thank the OMRF Rheumatology Center of Excellence and the Oklahoma Rheumatic Disease Research Cores Center for patient and control recruitment, sample processing and quality control. We also thank the patients who took part in this study.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Author disclaimer</title>
<p>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the US Government.</p>
</sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2024.1339250/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1339250/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hacbarth</surname> <given-names>E</given-names>
</name>
<name>
<surname>Kajdacsy-Balla</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever</article-title>. <source>Arthritis Rheum</source>. (<year>1986</year>) <volume>29</volume>:<page-range>1334&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.1780291105</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denny</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Yalavarthi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Thacker</surname> <given-names>SG</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sandy</surname> <given-names>AR</given-names>
</name>
<etal/>
</person-group>. <article-title>A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I ifns</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>184</volume>:<page-range>3284&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.0902199</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mistry</surname> <given-names>P</given-names>
</name>
<name>
<surname>Nakabo</surname> <given-names>S</given-names>
</name>
<name>
<surname>O'Neil</surname> <given-names>L</given-names>
</name>
<name>
<surname>Goel</surname> <given-names>RR</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Carmona-Rivera</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2019</year>) <volume>116</volume>:<page-range>25222&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1908576116</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villanueva</surname> <given-names>E</given-names>
</name>
<name>
<surname>Yalavarthi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Berthier</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Hodgin</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Khandpur</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus</article-title>. <source>J Immunol</source>. (<year>2011</year>) <volume>187</volume>:<page-range>538&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1100450</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahman</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sagar</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hanna</surname> <given-names>RN</given-names>
</name>
<name>
<surname>Lightfoot</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Mistry</surname> <given-names>P</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>CK</given-names>
</name>
<etal/>
</person-group>. <article-title>Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source>. (<year>2019</year>) <volume>78</volume>:<page-range>957&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/annrheumdis-2018-214620</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hochberg</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source>. (<year>1997</year>) <volume>40</volume>:<fpage>1725</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.1780400928</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aringer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Costenbader</surname> <given-names>K</given-names>
</name>
<name>
<surname>Daikh</surname> <given-names>D</given-names>
</name>
<name>
<surname>Brinks</surname> <given-names>R</given-names>
</name>
<name>
<surname>Mosca</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ramsey-Goldman</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus</article-title>. <source>Arthritis Rheumatol</source>. (<year>2019</year>) <volume>71</volume>:<page-range>1400&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.40930</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jog</surname> <given-names>NR</given-names>
</name>
<name>
<surname>Rane</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Lominadze</surname> <given-names>G</given-names>
</name>
<name>
<surname>Luerman</surname> <given-names>GC</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>RA</given-names>
</name>
<name>
<surname>McLeish</surname> <given-names>KR</given-names>
</name>
</person-group>. <article-title>The actin cytoskeleton regulates exocytosis of all neutrophil granule subsets</article-title>. <source>Am J Physiol Cell Physiol</source>. (<year>2007</year>) <volume>292</volume>:<page-range>C1690&#x2013;700</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajpcell.00384.2006</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munroe</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>YD</given-names>
</name>
<name>
<surname>Fife</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Robertson</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Guthridge</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Altered type ii interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification</article-title>. <source>Ann Rheum Dis</source>. (<year>2016</year>) <volume>75</volume>:<page-range>2014&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/annrheumdis-2015-208140</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slezak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Caruccio</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bennett</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zia</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Gene and microrna analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro rna-1 and -133a</article-title>. <source>J Transl Med</source>. (<year>2009</year>) <volume>7</volume>:<elocation-id>39</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1479-5876-7-39</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedersen</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Borup</surname> <given-names>R</given-names>
</name>
<name>
<surname>Fischer-Nielsen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mora-Jensen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fossum</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cowland</surname> <given-names>JB</given-names>
</name>
<etal/>
</person-group>. <article-title>Changes in gene expression during G-csf-induced emergency granulopoiesis in humans</article-title>. <source>J Immunol</source>. (<year>2016</year>) <volume>197</volume>:<page-range>1989&#x2013;99</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1502690</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Munroe</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Guthridge</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Bean</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Fife</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies</article-title>. <source>J Autoimmun</source>. (<year>2016</year>) <volume>74</volume>:<page-range>182&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaut.2016.06.001</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puapatanakul</surname> <given-names>P</given-names>
</name>
<name>
<surname>Chansritrakul</surname> <given-names>S</given-names>
</name>
<name>
<surname>Susantitaphong</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ueaphongsukkit</surname> <given-names>T</given-names>
</name>
<name>
<surname>Eiam-Ong</surname> <given-names>S</given-names>
</name>
<name>
<surname>Praditpornsilpa</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Interferon-inducible protein 10 and disease activity in systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms20194954</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munroe</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Vista</surname> <given-names>ES</given-names>
</name>
<name>
<surname>Guthridge</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Merrill</surname> <given-names>JT</given-names>
</name>
<name>
<surname>James</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare</article-title>. <source>Arthritis Rheumatol</source>. (<year>2014</year>) <volume>66</volume>:<page-range>1888&#x2013;99</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.38573</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasperini</surname> <given-names>S</given-names>
</name>
<name>
<surname>Marchi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Calzetti</surname> <given-names>F</given-names>
</name>
<name>
<surname>Laudanna</surname> <given-names>C</given-names>
</name>
<name>
<surname>Vicentini</surname> <given-names>L</given-names>
</name>
<name>
<surname>Olsen</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Gene expression and production of the monokine induced by ifn-gamma (Mig), ifn-inducible T cell alpha chemoattractant (I-tac), and ifn-gamma-inducible protein-10 (Ip-10) chemokines by human neutrophils</article-title>. <source>J Immunol</source>. (<year>1999</year>) <volume>162</volume>:<page-range>4928&#x2013;37</page-range>.</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ugarte-Berzal</surname> <given-names>E</given-names>
</name>
<name>
<surname>Boon</surname> <given-names>L</given-names>
</name>
<name>
<surname>Martens</surname> <given-names>E</given-names>
</name>
<name>
<surname>Rybakin</surname> <given-names>V</given-names>
</name>
<name>
<surname>Blockmans</surname> <given-names>D</given-names>
</name>
<name>
<surname>Vandooren</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Mmp-9/gelatinase B degrades immune complexes in systemic lupus erythematosus</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>538</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00538</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okubo</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kamiya</surname> <given-names>M</given-names>
</name>
<name>
<surname>Urano</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Nishi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Herter</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Mayadas</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Lactoferrin suppresses neutrophil extracellular traps release in inflammation</article-title>. <source>EBioMedicine</source>. (<year>2016</year>) <volume>10</volume>:<page-range>204&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ebiom.2016.07.012</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coit</surname> <given-names>P</given-names>
</name>
<name>
<surname>Yalavarthi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ognenovski</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Hasni</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wren</surname> <given-names>JD</given-names>
</name>
<etal/>
</person-group>. <article-title>Epigenome profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils</article-title>. <source>J Autoimmun</source>. (<year>2015</year>) <volume>58</volume>:<fpage>59</fpage>&#x2013;<lpage>66</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaut.2015.01.004</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carmona-Rivera</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kaplan</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>Low-density granulocytes: A distinct class of neutrophils in systemic autoimmunity</article-title>. <source>Semin Immunopathol</source>. (<year>2013</year>) <volume>35</volume>:<page-range>455&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00281-013-0375-7</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurol</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>W</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>Q</given-names>
</name>
</person-group>. <article-title>Micrornas in neutrophils: potential next generation therapeutics for inflammatory ailments</article-title>. <source>Immunol Rev</source>. (<year>2016</year>) <volume>273</volume>:<fpage>29</fpage>&#x2013;<lpage>47</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imr.12450</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsen</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Hother</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hager</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pedersen</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Theilgaard-Monch</surname> <given-names>K</given-names>
</name>
<name>
<surname>Borregaard</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Microrna profiling in human neutrophils during bone marrow granulopoiesis and in vivo exudation</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>8</volume>:<elocation-id>e58454</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0058454</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Che</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Mir-223: an immune regulator in infectious disorders</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>781815</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.781815</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>